secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001193125-23-089004
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex raises ~$2.04M in private placement at $0.41/share; insider participation
--------------------------------------------------------------------------------

- Sold 4,975,608 shares at $0.41/share for gross proceeds of ~$2.04 million to three investors, including affiliates of CEO and chairman.
- Proceeds will fund development and clinical trials of lead drug candidate pepinemab in cancer and neurodegenerative disease, plus working capital.
- FCMI Parent Co., controlled by chairman Albert D. Friedberg, committed to purchase up to an additional $2.96 million of shares on or before May 15, 2023.
- Albert Friedberg covenanted to vote his shares in excess of 40% proportionately with other holders; registration rights granted to non-affiliated investor.
- Shares issued in private placement exempt from registration under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/0001193125-23-089004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/d462228d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-089004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer